Exciting news in the world of Acromegaly new drug development

Recently we told you about Chiasma’s latest news in both Phase 3 clinical trials of oral octreotide capsules product candidates, which are well on the way. You can read more about the company and the trial here.

Today, we also report on developments at Crinetics Pharmaceutical and their current effort to recruit patients for two ongoing studies in Acromegaly. Crinetics focuses on the discovery and development of new therapies for rare endocrine diseases and endocrine-related tumors. These specific studies also focus on new oral therapies for the treatment of Acromegaly.

If you – or someone you know – would like to learn more about these trials and see if you can participate, click here for details and a direct link to the studies.

For additional questions, email clinicaltrials@crinetics.com.

Currently, Crinetics has a limited number of sites open for these studies but expect more to come online over the next few months.

We will keep you informed on any additional developments.

© 2019, Pituitary World News. All rights reserved.